HLS Therapeutics (TSX:HLS) Forward Dividend Yield % : 0.00% (As of May. 28, 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Forward Dividend Yield %?

As of today (2024-05-28), the Forward Annual Dividend Yield of HLS Therapeutics is 0.00%.

As of today (2024-05-28), the Trailing Annual Dividend Yield of HLS Therapeutics is 1.29%.

TSX:HLS's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.865
* Ranked among companies with meaningful Forward Dividend Yield % only.

HLS Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was C$0.00.

During the past 12 months, HLS Therapeutics's average Dividends Per Share Growth Rate was -75.60% per year. During the past 3 years, the average Dividends Per Share Growth Rate was -19.50% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 10.60% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of HLS Therapeutics was 59.00% per year. The lowest was -19.50% per year. And the median was 22.80% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of HLS Therapeutics's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Forward Dividend Yield % falls into.

HLS Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

HLS Therapeutics (TSX:HLS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

HLS Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (TSX:HLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

Executives

Polar Asset Management Partners Inc.

10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines